John Normile is a leading Hatch-Waxman patent litigator who has 30 years experience representing innovative pharmaceutical companies. He also has represented various plaintiffs and defendants in intellectual property cases involving diverse technologies. Among the clients for whom he has worked are Bic, Fenwal, King Pharmaceuticals, Merck, Purdue Pharma L.P., and Schweitzer-Mauduit.
John has acted as trial counsel before several of the federal district and appellate courts including the Federal Circuit and the U.S. Supreme Court. He has represented pharmaceutical companies in the enforcement of patents concerning blockbuster drugs including OxyContin®, Butrans®, Hysingla®, Skelaxin®, Buspar®, and MitomycinC®. John also has experience representing clients as lead counsel in USPTO post-grant proceedings. These representations have involved at least 50 district court actions and various appearances in the USPTO and the Federal Circuit. John is an adjunct professor at Fordham Law School, where he has taught a course in patent litigation for the past 20 years.